# Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

> **NCT03333343** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 105 (actual)

## Conditions studied

- EGFR-mutant Non-small Cell Lung Cancer

## Interventions

- **DRUG:** EGF816
- **DRUG:** trametinib
- **DRUG:** ribociclib
- **DRUG:** LXH254
- **DRUG:** INC280
- **DRUG:** gefitinib

## Key facts

- **NCT ID:** NCT03333343
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-01-29
- **Primary completion:** 2026-10-05
- **Final completion:** 2026-10-05
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03333343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03333343, "Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03333343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*